News

Cianferoni discusses how pollen food allergy syndrome contributes to eosinophilic esophagitis (EoE) and potential management strategies.

The regulatory agency accepted the BLA's filing and assigned a target action date of August 31, 2025.

These data presented at AAD 2025 indicate sustained 2-year disease control in key hidradenitis suppurativa (HS) symptoms with bimekizumab-bkzx treatment.

At AAAAI 2025, Cianferoni described molecular mechanisms of pollen food allergy syndrome.

The pivotal trial showed superior weight loss to placebo at 68 weeks but fell short of ≥25% weight loss initially expected by Novo Nordisk.

Omalizumab-igec is approved in 2 formulations for the treatment of moderate to severe persistent asthma, CRSwNP, IgE-mediated food allergy, and CSU.

Topline results from the phase 2b ANTHEM-UC study show all 3 doses of once-daily oral icotrokinra met the primary endpoint for clinical response.

This AAD 2025 interview with Bhutani covers some of the takeaways from her presentation on use of JAK inhibitors for alopecia areata among pregnant or breastfeeding women.

Psychosocial interventions reduced depressive symptoms in CKD but did not have a significant impact on patients’ quality of life.

This interview with Melinda Gooderham, MD, covers recent findings from the phase 3 ARRECTOR trial on roflumilast foam 0.3% in scalp and body psoriasis.

This interview at the Skin of Color Society (SOCS) Scientific Symposium features Elbuluk describing her plans as newly-elected president of SOCS.

An analysis of data from the DELTA program at AAD 2025 sheds light on the efficacy of delgocitinib for chronic hand eczema.

Crystal Aguh, MD, discusses a study from AAD 2025 examining HbA1c levels and outcomes in CCCA.

This interview with Chovatiya highlights his portion of the ‘Skin of Color’ talk at the American Academy of Dermatology conference.

Data at AAD 2025 and an announcement from Amgen provide insight into the potential role of rocatinlimab in atopic dermatitis.

This interview with Snyder features a discussion on recent findings on remibrutinib among patients with chronic spontaneous urticaria, also known as CSU.

New data from AAD 2025 and topline results from the ICONIC program underline the potential of icotrokinra in moderate to severe plaque psoriasis.

Robert Bissonnette, MD, discusses data from the ICONIC-LEAD trial and the potential role of icotrokinra in plaque psoriasis.

In this interview at AAD 2025, Craiglow speaks on her team’s late-breaking findings on baricitinib among adolescents with severe alopecia areata.

LIBERTY-BP ADEPT provides further insight into the potential of dupilumab in bullous pemphigoid ahead of the June 2025 PDUFA date.

Data from AAD 2025 examine the effect of GLP-1 RAs on HS among patients with overweight or obesity.

Phase 3 data from ruxolitinib cream 1.5% presented at AAD 2025 demonstrate the potential of the topical agent in prurigo nodularis.

This interview covers the findings presented at AAD 2025 from the SIGNAL-AA study on bempikibart for alopecia areata.

Stein Gold highlights her team's findings on tapinarof cream (Vtama) 1% from the 48-week ADORING 3 extension for those aged 2 to 17 with atopic dermatitis.

David Rosmarin, MD, discusses results from ADORING 3 presented at AAD 2025.

Our top 5 headlines include 5 key FDA decisions, including the first approval for stroke in 3 decades, an expanded indication for pediatric anaphylaxis, and more!

Susan Taylor, MD, discusses a study examining the effect of GLP-1 RA use relative to nonuse in central centrifugal cicatricial alopecia at AAD 2025.

This month in review covers key psychiatry updates, including the latest FDA decisions, antidepressant use in pregnancy, and the latest episode of Medical Ethics Unpacked.